{"pmid":32461245,"title":"Ethical guidelines for deliberately infecting volunteers with COVID-19.","text":["Ethical guidelines for deliberately infecting volunteers with COVID-19.","Global fatalities related to COVID-19 are expected to be high in 2020-2021. Developing and delivering a vaccine may be the most likely way to end the pandemic. If it were possible to shorten this development time by weeks or months, this may have a significant effect on reducing deaths. Phase II and phase III trials could take less long to conduct if they used human challenge methods-that is, deliberately infecting participants with COVID-19 following inoculation. This article analyses arguments for and against such methods and provides suggested broad guidelines for regulators, researchers and ethics committees when considering these matters. It concludes that it may be possible to maintain current ethical standards yet still permit human challenge trials in a context where delay is critical. The implications are that regulators and researchers need to work together now to design robust but short trials and streamline ethics approval processes so that they are in place when applications for trials are made.","J Med Ethics","Richards, Adair D","32461245"],"abstract":["Global fatalities related to COVID-19 are expected to be high in 2020-2021. Developing and delivering a vaccine may be the most likely way to end the pandemic. If it were possible to shorten this development time by weeks or months, this may have a significant effect on reducing deaths. Phase II and phase III trials could take less long to conduct if they used human challenge methods-that is, deliberately infecting participants with COVID-19 following inoculation. This article analyses arguments for and against such methods and provides suggested broad guidelines for regulators, researchers and ethics committees when considering these matters. It concludes that it may be possible to maintain current ethical standards yet still permit human challenge trials in a context where delay is critical. The implications are that regulators and researchers need to work together now to design robust but short trials and streamline ethics approval processes so that they are in place when applications for trials are made."],"journal":"J Med Ethics","authors":["Richards, Adair D"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32461245","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1136/medethics-2020-106322","keywords":["ethics committees/consultation","informed consent","policy guidelines/inst","public policy","research ethics","review boards/review cttes"],"weight":0,"_version_":1668079521316732928,"score":9.490897,"similar":[{"pmid":32469074,"title":"Paying Participants in COVID-19 Trials.","text":["Paying Participants in COVID-19 Trials.","A variety of trials are in development and underway to examine potential interventions for the treatment and prophylaxis of novel coronavirus disease 2019 (COVID-19). How should we think about offering payment to participants in these trials? Payment for research participation is ethically contentious even under ideal circumstances, and pandemics are far from ideal. Here, we review the three functions of research payment-reimbursement, compensation, and incentive-and identify heightened and novel ethical concerns in the context of a global pandemic. We argue that COVID-19 trial participants should usually be offered reimbursement for research-related expenses, as well as compensation for their time and effort, as is true for other types of research under usual circumstances. Given increased risk of undue influence against pandemic background conditions, incentive payment should be avoided unless essential to recruitment and retention in important trials whose social value outweighs this risk. Where essential, however, incentives can be ethically permissible, so long as reasonable efforts are made to minimize the possibility of undue influence.","J Infect Dis","Largent, Emily A","Lynch, Holly Fernandez","32469074"],"abstract":["A variety of trials are in development and underway to examine potential interventions for the treatment and prophylaxis of novel coronavirus disease 2019 (COVID-19). How should we think about offering payment to participants in these trials? Payment for research participation is ethically contentious even under ideal circumstances, and pandemics are far from ideal. Here, we review the three functions of research payment-reimbursement, compensation, and incentive-and identify heightened and novel ethical concerns in the context of a global pandemic. We argue that COVID-19 trial participants should usually be offered reimbursement for research-related expenses, as well as compensation for their time and effort, as is true for other types of research under usual circumstances. Given increased risk of undue influence against pandemic background conditions, incentive payment should be avoided unless essential to recruitment and retention in important trials whose social value outweighs this risk. Where essential, however, incentives can be ethically permissible, so long as reasonable efforts are made to minimize the possibility of undue influence."],"journal":"J Infect Dis","authors":["Largent, Emily A","Lynch, Holly Fernandez"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32469074","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1093/infdis/jiaa284","keywords":["covid","informed consent","payment","research ethics","undue influence"],"weight":0,"_version_":1668167109945851905,"score":172.42764},{"pmid":32441894,"title":"Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.","text":["Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.","Human challenge trials to test the efficacy of vaccine candidates against SARS-CoV-2, the novel coronavirus behind Covid-19, could save considerable time and many lives. But they may initially seem unethical because they expose healthy volunteers to a live virus that is killing many people and for which no cure exists. This article argues that this is not the correct test of their ethics. The correct test is comparative. And in the special circumstances of the Covid-19 pandemic, human challenge trials meet the correct test better than standard efficacy testing would.","Ethics Hum Res","Eyal, Nir","32441894"],"abstract":["Human challenge trials to test the efficacy of vaccine candidates against SARS-CoV-2, the novel coronavirus behind Covid-19, could save considerable time and many lives. But they may initially seem unethical because they expose healthy volunteers to a live virus that is killing many people and for which no cure exists. This article argues that this is not the correct test of their ethics. The correct test is comparative. And in the special circumstances of the Covid-19 pandemic, human challenge trials meet the correct test better than standard efficacy testing would."],"journal":"Ethics Hum Res","authors":["Eyal, Nir"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441894","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/eahr.500056","keywords":["covid-19","coronavirus","human challenge studies","randomized controlled trials","research ethics","risk taking","vaccines"],"weight":0,"_version_":1667535119440674816,"score":165.83655},{"pmid":32410347,"title":"Equitably Sharing the Benefits and Burdens of Research: Covid-19 Raises the Stakes.","text":["Equitably Sharing the Benefits and Burdens of Research: Covid-19 Raises the Stakes.","One of the central principles of research ethics is that the benefits and burdens of research with human participants should be equitably distributed. This principle has important implications for where research will be conducted, how participants will be recruited, what questions will be investigated, and who will control the distribution of any innovations that result. In the context of Covid-19, key issues include providing support to clinical trials in low- and middle-income countries, without taking needed resources away from other critical clinical and public health needs; designing recruitment strategies likely to generate sufficient enrollment from groups that have been disproportionately burdened by the virus, such as African Americans; supporting studies designed to improve outcomes in high-risk environments, such as nursing homes and group homes for the developmentally disabled; and ensuring that the medical products resulting from research are made available throughout the world at an affordable price. If clinical trials are not designed with equity considerations consciously in mind, the response to the pandemic may further exacerbate disparities in health status between population groups.","Ethics Hum Res","Coleman, Carl H","32410347"],"abstract":["One of the central principles of research ethics is that the benefits and burdens of research with human participants should be equitably distributed. This principle has important implications for where research will be conducted, how participants will be recruited, what questions will be investigated, and who will control the distribution of any innovations that result. In the context of Covid-19, key issues include providing support to clinical trials in low- and middle-income countries, without taking needed resources away from other critical clinical and public health needs; designing recruitment strategies likely to generate sufficient enrollment from groups that have been disproportionately burdened by the virus, such as African Americans; supporting studies designed to improve outcomes in high-risk environments, such as nursing homes and group homes for the developmentally disabled; and ensuring that the medical products resulting from research are made available throughout the world at an affordable price. If clinical trials are not designed with equity considerations consciously in mind, the response to the pandemic may further exacerbate disparities in health status between population groups."],"journal":"Ethics Hum Res","authors":["Coleman, Carl H"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32410347","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1002/eahr.500055","keywords":["covid-19","lmic countries","benefits and burdens of research","clinical trials","equity in clinical research","health disparities","research ethics"],"locations":["African Americans"],"countries":["United States"],"countries_codes":["USA|United States"],"weight":0,"_version_":1666897319197409280,"score":165.60835},{"pmid":32392334,"title":"COVID-19 Clinical Trial Oversight at a Major Academic Medical Center: Approach of the Michigan Medicine COVID-19 Clinical Trial Committees.","text":["COVID-19 Clinical Trial Oversight at a Major Academic Medical Center: Approach of the Michigan Medicine COVID-19 Clinical Trial Committees.","Clinicians - eager to offer the best care in the absence of guiding data - have provided patients with COVID-19 diverse clinical interventions. This usage has led to perceptions of efficacy of some interventions that, while receiving media coverage, lack robust evidence. Moving forward, randomized controlled clinical trials (RCTs) are necessary to ensure that clinicians can treat patients effectively during this outbreak and the next. To do so, academic medical centers must address two key research issues: (1) how to effectively and efficiently determine which trials have the best chance of benefiting current and future patients, and (2) how to establish a transparent and ethical process for subject recruitment while maintaining research integrity and without overburdening patients or staff. We share here the current methods used by the University of Michigan to address these issues.","Clin Infect Dis","Spector-Bagdady, Kayte","Higgins, Peter D R","Lok, Anna S","32392334"],"abstract":["Clinicians - eager to offer the best care in the absence of guiding data - have provided patients with COVID-19 diverse clinical interventions. This usage has led to perceptions of efficacy of some interventions that, while receiving media coverage, lack robust evidence. Moving forward, randomized controlled clinical trials (RCTs) are necessary to ensure that clinicians can treat patients effectively during this outbreak and the next. To do so, academic medical centers must address two key research issues: (1) how to effectively and efficiently determine which trials have the best chance of benefiting current and future patients, and (2) how to establish a transparent and ethical process for subject recruitment while maintaining research integrity and without overburdening patients or staff. We share here the current methods used by the University of Michigan to address these issues."],"journal":"Clin Infect Dis","authors":["Spector-Bagdady, Kayte","Higgins, Peter D R","Lok, Anna S"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32392334","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1093/cid/ciaa560","keywords":["covid-19","ethics","informed consent","randomized clinical trial","research ethics"],"topics":["Treatment"],"weight":1,"_version_":1666528580160454657,"score":156.77898},{"pmid":32414757,"title":"Ethical considerations for epidemic vaccine trials.","text":["Ethical considerations for epidemic vaccine trials.","Vaccines are a powerful measure to protect the health of individuals and to combat outbreaks such as the COVID-19 pandemic. An ethical dilemma arises when one effective vaccine has been successfully developed against an epidemic disease and researchers seek to test the efficacy of another vaccine for the same pathogen in clinical trials involving human subjects. On the one hand, there are compelling reasons why it would be unethical to trial a novel vaccine when an effective product exists already. First, it is a firm principle of medical ethics that an effective treatment or vaccine should not be withheld from patients if their life may depend on it. Second, since epidemic outbreaks often emerge in settings with less-resourced health systems, there is a pronounced risk that any trial withholding an effective vaccine would disproportionately affect the vulnerable populations that historically have been exploited for biomedical research. Third, clinical trials for novel vaccines may be at odds with efforts to control active outbreaks. On the other hand, it may be justified to conduct a trial for a candidate vaccine if it is expected to have certain advantages compared with the existing product. This essay discusses key factors for comparing vaccines against epidemic pathogens, including immunological, logistical and economic considerations. Alongside a case study of the development of vaccines for Ebola, the essay seeks to establish a general framework that should be expanded and populated by immunologists, epidemiologists, economists and bioethicists, and ultimately could be applied to the case of COVID-19 vaccines.","J Med Ethics","Monrad, Joshua Teperowski","32414757"],"abstract":["Vaccines are a powerful measure to protect the health of individuals and to combat outbreaks such as the COVID-19 pandemic. An ethical dilemma arises when one effective vaccine has been successfully developed against an epidemic disease and researchers seek to test the efficacy of another vaccine for the same pathogen in clinical trials involving human subjects. On the one hand, there are compelling reasons why it would be unethical to trial a novel vaccine when an effective product exists already. First, it is a firm principle of medical ethics that an effective treatment or vaccine should not be withheld from patients if their life may depend on it. Second, since epidemic outbreaks often emerge in settings with less-resourced health systems, there is a pronounced risk that any trial withholding an effective vaccine would disproportionately affect the vulnerable populations that historically have been exploited for biomedical research. Third, clinical trials for novel vaccines may be at odds with efforts to control active outbreaks. On the other hand, it may be justified to conduct a trial for a candidate vaccine if it is expected to have certain advantages compared with the existing product. This essay discusses key factors for comparing vaccines against epidemic pathogens, including immunological, logistical and economic considerations. Alongside a case study of the development of vaccines for Ebola, the essay seeks to establish a general framework that should be expanded and populated by immunologists, epidemiologists, economists and bioethicists, and ultimately could be applied to the case of COVID-19 vaccines."],"journal":"J Med Ethics","authors":["Monrad, Joshua Teperowski"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32414757","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1136/medethics-2020-106235","keywords":["clinical trials","ethics"],"topics":["Treatment"],"weight":1,"_version_":1666994545957535744,"score":140.2427}]}